Anindita Das

indian association for the cultivation of science

H指数:47

被引数:6,304

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Circularly Polarized Luminescence (CPL)-Active Homo- and Heterostructures by Surface-Catalyzed Secondary Supramolecular Polymerization

表面催化的二次超分子聚合制备的圆偏振发光(CPL)活性同质与异质结构

Small

IF12.1

2026-03-100

PRE

Targeted Ganglionated Plexi Ablation With Nanoformulated Calcium Suppresses Postoperative AF Via Vagosympatholytic and Anti-Inflammatory Effects

JACC-CLINICAL ELECTROPHYSIOLOGY

IF7.7

2025-01-010

PRE

Differential bone morphology and hypoxia activity in skeletal metastases of ER+ and ER- breast cancer

COMMUNICATIONS BIOLOGY

IF5.1

2024-11-210

OAAI

Functional-Molecular Mechanisms of Sympathetic-Parasympathetic Dysfunction in PVC-Induced Cardiomyopathy Revealed by Dual Stressor PVC-Exercise Challenge

JACC-CLINICAL ELECTROPHYSIOLOGY

IF7.7

2024-10-012

PRE

Re-sensitizing the Refractory Breast Cancer Bone Metastasis to Endocrine Therapies

CANCER RESEARCH

IF16.6

2024-05-020

PRE

Integrated Analysis of lncRNA-miRNA-mRNA Regulatory Network in Rapamycin-Induced Cardioprotection against Ischemia/Reperfusion Injury in Diabetic Rabbits

CELLS

IF5.2

2023-12-124

OAAI

Endogenously Released Factors From DoxorubicinTreated Breast Cancer Spheroids Contribute to Toxicity in Human Cardiomyocytes: Protective Effect of Combination Therapy With PDE5mTOR Inhibitors

CIRCULATION

IF38.6

2023-11-070

PRE

Partial agonism in heteromeric GLUK2/GLUK5 kainate receptor

PROTEINS-STRUCTURE FUNCTION AND BIOINFORMATICS

IF2.8

2023-08-011

PRE

Beyond Erectile Dysfunction: cGMP-Specific Phosphodiesterase 5 Inhibitors for Other Clinical Disorders

超越勃起功能障碍: cGMP特异性磷酸二酯酶5抑制剂治疗其他临床疾病

ANNUAL REVIEW OF PHARMACOLOGY AND TOXICOLOGY

IF13.1

2023-01-2036

Treating diabetes with combination of phosphodiesterase 5 inhibitors and hydroxychloroquine-a possible prevention strategy for COVID-19?

磷酸二酯酶5抑制剂和羟氯喹联合治疗糖尿病-可能的新型冠状病毒肺炎预防策略？

MOLECULAR AND CELLULAR BIOCHEMISTRY

IF3.7

2022-08-293

OAAI

Cardiac Gene Therapy With Relaxin Receptor 1 Overexpression Protects Against Acute Myocardial Infarction

JACC-BASIC TO TRANSLATIONAL SCIENCE

IF7.2

2022-01-018

Role of phosphodiesterase 1 in the pathophysiology of diseases and potential therapeutic opportunities

磷酸二酯酶1在疾病的病理生理中的作用和潜在的治疗机会

PHARMACOLOGY & THERAPEUTICS

IF12.5

2021-10-0127

OAAI

Cardiovascular risks and toxicity - The Achilles heel of androgen deprivation therapy in prostate cancer patients

心血管风险和毒性-前列腺癌患者雄激素剥夺治疗的致命弱点

BIOCHIMICA ET BIOPHYSICA ACTA-REVIEWS ON CANCER

IF8.3

2020-08-0131

OAAI

PDE5 inhibitor sildenafil attenuates cardiac microRNA 214 upregulation and pro-apoptotic signaling after chronic alcohol ingestion in mice

PDE5抑制剂西地那非减弱小鼠慢性酒精摄入后心脏microRNA 214上调和促凋亡信号

MOLECULAR AND CELLULAR BIOCHEMISTRY

IF3.7

2020-06-136

PREAI

B7-33, a Functionally Selective Relaxin Receptor 1 Agonist, Attenuates Myocardial Infarction-Related Adverse Cardiac Remodeling in Mice

JOURNAL OF THE AMERICAN HEART ASSOCIATION

IF5.3

2020-04-2115

OAAI

Remote Ischemic Pre-Conditioning Attenuates Adverse Cardiac Remodeling and Mortality Following Doxorubicin Administration in Mice

JACC: CARDIOONCOLOGY

IF12.8

2019-12-0118

OAAI

Metformin attenuates ER stress-induced mitochondrial dysfunction

TRANSLATIONAL RESEARCH

IF5.9

2017-12-0171

OAAI

Chronic treatment with novel nanoformulated micelles of rapamycin, Rapatar, protects diabetic heart against ischaemia/reperfusion injury

BRITISH JOURNAL OF PHARMACOLOGY

IF7.7

2017-11-2414

OAAI

Reperfusion therapy with recombinant human relaxin-2 (Serelaxin) attenuates myocardial infarct size and NLRP3 inflammasome following ischemia/reperfusion injury via eNOS-dependent mechanism

CARDIOVASCULAR RESEARCH

IF13.3

2017-01-1089

OAAI

Beet root juice protects against doxorubicin toxicity in cardiomyocytes while enhancing apoptosis in breast cancer cells

MOLECULAR AND CELLULAR BIOCHEMISTRY

IF3.7

2016-08-2626

PREAI

Anindita Das

个人简介

教育背景

工作经历

荣誉奖项

研究方向